IL90730A0 - Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates - Google Patents

Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates

Info

Publication number
IL90730A0
IL90730A0 IL90730A IL9073089A IL90730A0 IL 90730 A0 IL90730 A0 IL 90730A0 IL 90730 A IL90730 A IL 90730A IL 9073089 A IL9073089 A IL 9073089A IL 90730 A0 IL90730 A0 IL 90730A0
Authority
IL
Israel
Prior art keywords
complexes
antibody conjugates
bifunctional chelants
chelants
macrocyclic bifunctional
Prior art date
Application number
IL90730A
Other languages
English (en)
Original Assignee
Dow Chemical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dow Chemical Co filed Critical Dow Chemical Co
Publication of IL90730A0 publication Critical patent/IL90730A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1084—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin
    • A61K51/109—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being a hybrid immunoglobulin immunoglobulins having two or more different antigen-binding sites or multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2123/00—Preparations for testing in vivo

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL90730A 1988-06-24 1989-06-23 Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates IL90730A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21149688A 1988-06-24 1988-06-24
US37095689A 1989-06-21 1989-06-21

Publications (1)

Publication Number Publication Date
IL90730A0 true IL90730A0 (en) 1990-01-18

Family

ID=26906194

Family Applications (1)

Application Number Title Priority Date Filing Date
IL90730A IL90730A0 (en) 1988-06-24 1989-06-23 Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates

Country Status (20)

Country Link
US (1) US5435990A (da)
EP (2) EP0353450B1 (da)
JP (1) JP2831073B2 (da)
KR (1) KR0137930B1 (da)
AT (1) ATE120457T1 (da)
AU (1) AU634167B2 (da)
BR (1) BR8907507A (da)
CA (1) CA1341373C (da)
DE (2) DE68921941T2 (da)
DK (1) DK175393B1 (da)
ES (1) ES2013978A4 (da)
FI (2) FI103792B1 (da)
GR (1) GR900300034T1 (da)
HK (1) HK60696A (da)
HU (1) HU219485B (da)
IE (1) IE67273B1 (da)
IL (1) IL90730A0 (da)
NO (1) NO179008C (da)
NZ (1) NZ229700A (da)
WO (1) WO1989012631A1 (da)

Families Citing this family (104)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5422096A (en) * 1985-05-08 1995-06-06 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
US5250285A (en) * 1985-05-08 1993-10-05 The General Hospital Corporation Hydroxy-aryl metal chelates for diagnostic NMR imaging
DE68927479T2 (de) * 1988-05-02 1997-04-03 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
US5756065A (en) * 1988-06-24 1998-05-26 The Dow Chemical Company Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents
JP2930708B2 (ja) * 1988-12-23 1999-08-03 ザ ダウ ケミカル カンパニー イソチオシアナト官能化金属錯体の製造方法
US5914095A (en) * 1989-04-07 1999-06-22 Salutar, Inc. Polychelants containg amide bonds
US5686410A (en) * 1989-07-20 1997-11-11 Novartis Ag Polypeptide derivatives
JPH05503072A (ja) * 1989-08-28 1993-05-27 ザ・ゼネラル・ホスピタル・コーポレーション 診断用ｎｍｒ映像化の為のヒドロキシ―アリール金属キレート
DE3938992A1 (de) 1989-11-21 1991-05-23 Schering Ag Kaskadenpolymer-gebundene komplexbildner, deren komplexe und konjugate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische mittel
US5410043A (en) * 1991-12-06 1995-04-25 Schering Aktiengesellschaft Process for the production of mono-N-substituted tetraaza macrocycles
EP0565930A1 (en) * 1992-03-27 1993-10-20 Nihon Medi-Physics Co., Ltd. Tetraazacyclododecane tetraacetic acid derivatives and the use thereof as diagnostic agents
JPH07505886A (ja) * 1992-04-13 1995-06-29 ザ　ダウ　ケミカル　カンパニー マクロ環状キレート化剤の製造方法及びキレートの形成並びにその結合体
US5310535A (en) * 1992-04-24 1994-05-10 The Dow Chemical Company Carboxamide modified polyamine chelators and radioactive complexes thereof for conjugation to antibodies
DE4218744C2 (de) * 1992-06-04 1997-11-06 Schering Ag Verfahren zur Herstellung von N-ß-Hxdroxyalkyl-tri-N-carboxylalkyl-1,4,7,10-tetraazacyclododecan- und N-ß-Hydroxyalkyl-tri-N-carboxyalkyl-1,4,8,11-tetraazacyclotetradecan-Derivaten und deren Metallkomplexe
US5505931A (en) * 1993-03-04 1996-04-09 The Dow Chemical Company Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
US5462725A (en) * 1993-05-06 1995-10-31 The Dow Chemical Company 2-pyridylmethylenepolyazamacrocyclophosphonic acids, complexes and derivatives thereof, for use as contrast agents
ES2156143T3 (es) * 1993-12-30 2001-06-16 Guerbet Sa Ligandos poliaminados, complejos metalicos, procedimiento de preparacion, aplicaciones diagnosticas y terapeuticas.
KR970700698A (ko) * 1994-01-07 1997-02-12 에프. 지. 엠. 헤르만스; 이. 에이취. 리링크 폴리아미노카르복실레이트 킬레이트제(new polyaminocarboxylate chelators)
AU2194695A (en) * 1994-03-28 1995-10-17 Regents Of The University Of California, The Method for preparing radionuclide-labeled chelating agent-ligand complexes
US5582814A (en) * 1994-04-15 1996-12-10 Metasyn, Inc. 1-(p-n-butylbenzyl) DTPA for magnetic resonance imaging
US6693190B1 (en) 1994-05-11 2004-02-17 Bracco International B.V. Enhanced relaxivity monomeric and multimeric compounds
JPH10505357A (ja) * 1994-09-07 1998-05-26 ザ ダウ ケミカル カンパニー マクロ環式キレート化剤の製造法およびキレートの生成並びにその結合体
US7597886B2 (en) * 1994-11-07 2009-10-06 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
US7820798B2 (en) * 1994-11-07 2010-10-26 Human Genome Sciences, Inc. Tumor necrosis factor-gamma
TW319763B (da) 1995-02-01 1997-11-11 Epix Medical Inc
DE19505960A1 (de) * 1995-02-21 1996-08-22 Deutsches Krebsforsch Konjugat zur individuellen Dosierung von Arzneimitteln
TR28540A (tr) * 1995-03-16 1996-09-30 Guerbet Sa Poliamine edilmis baglayicilar ve bunlarin metal kompleksleri.
US5874573A (en) * 1995-06-26 1999-02-23 Concat, Inc. Compounds with chelation affinity and selectivity for first transition series elements: use in medical therapy
US6348581B1 (en) 1996-10-31 2002-02-19 The Dow Chemical Company High affinity humanized anti-TAG-72 monoclonalantibodies
WO1999043287A2 (en) * 1998-02-25 1999-09-02 Biotraces, Inc. Phosphate-based dendrimers for bioassays
US6231832B1 (en) 1998-03-23 2001-05-15 Brookhaven Science Associates Radiopharmaceutical stannic Sn-117m chelate compositions and methods of use
US6040124A (en) * 1998-11-20 2000-03-21 Eastman Kodak Company Imaging element with biaxially oriented sheet with fluoropolymer
CA2363779A1 (en) 1999-02-26 2000-08-31 Human Genome Sciences, Inc. Human endokine alpha and methods of use
US6696551B1 (en) * 1999-03-23 2004-02-24 The United States Of America As Represented By The Department Of Health And Human Services 225Ac-HEHA and related compounds, methods of synthesis and methods of use
LU90544B1 (en) * 2000-03-14 2001-09-17 Europ Economic Community Bifunctional chelating agent
US20030171267A1 (en) 2000-04-12 2003-09-11 Rosen Craig A. Albumin fusion proteins
AU2001282856A1 (en) 2000-06-15 2001-12-24 Human Genome Sciences, Inc. Human tumor necrosis factor delta and epsilon
ES2609016T3 (es) 2000-06-16 2017-04-18 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a BLyS
WO2002096948A2 (en) * 2001-01-29 2002-12-05 Idec Pharmaceuticals Corporation Engineered tetravalent antibodies and methods of use
BR0206985A (pt) * 2001-01-29 2005-04-19 Idec Pharma Corp Anticorpos modificados e métodos de uso
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
ES2437992T3 (es) 2001-05-25 2014-01-15 Human Genome Sciences, Inc. Anticuerpos que se unen inmunoespecíficamente a los receptores de TRAIL
DE10135356C1 (de) * 2001-07-20 2003-04-17 Schering Ag Makrocyclische Metallkomplexe und deren Verwendung zur Herstellung von Konjugaten mit Biomolekülen
EP1997829A1 (en) 2001-12-21 2008-12-03 Human Genome Sciences, Inc. Albumin fusion proteins
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
CA2480052A1 (en) * 2002-04-01 2003-10-16 Human Genome Sciences, Inc. Antibodies that specifically bind to gmad
EP1499352A4 (en) 2002-04-12 2006-10-11 Medimmune Inc ANTI-INTERLEUKIN-9 RECOMBINANT ANTIBODIES
EP1531848A4 (en) * 2002-06-10 2007-03-28 Vaccinex Inc DIFFERENTIAL EXPRESSED GENE IN BREAST AND BLADDER CANCER AND CODED POLYPEPTIDE
US20030086868A1 (en) * 2002-08-12 2003-05-08 Dangshe Ma Actinium-225 complexes and conjugates for radioimmunotherapy
US7214545B2 (en) * 2003-04-28 2007-05-08 The Regents Of The University Of California Element-coded affinity tags
EP1660519B1 (en) * 2003-07-29 2014-05-14 Immunomedics, Inc. Conjugates comprising 2-[18F]fluoro-2-deoxy-D-glucose and a peptide molecule
CA2534426A1 (en) * 2003-08-08 2005-02-17 Barnes-Jewish Hospital Emulsion particles for imaging and therapy and methods of use thereof
US7259249B2 (en) 2003-12-01 2007-08-21 Immunomedics, Inc. Method for preparing conjugates of proteins and chelating agents
JP5042631B2 (ja) * 2003-12-04 2012-10-03 バクシネックス インコーポレーティッド アポトーシス腫瘍細胞上に露出した細胞内抗原をターゲッティングすることによって腫瘍細胞を死滅させる方法
US20050226883A1 (en) * 2004-02-06 2005-10-13 Paul Averback Humanized antibody
HUE027902T2 (en) 2004-02-09 2016-11-28 Human Genome Sciences Inc Corp Service Company Albumin fusion proteins
EP1786463A4 (en) * 2004-03-26 2009-05-20 Human Genome Sciences Inc ANTIBODY AGAINST NOGO RECEPTOR
US7504088B2 (en) 2004-06-09 2009-03-17 Kereos, Inc. Lipophilic derivatives of chelate monoamides
EP1778699A4 (en) * 2004-08-10 2009-02-25 Dow Global Technologies Inc TARGETING OF CHELANTS AND CHELATES
EP2301969B1 (en) 2005-05-06 2015-12-23 ZymoGenetics, Inc. IL-31 monoclonal antibodies and methods of use
CA2631784A1 (en) * 2005-11-29 2007-06-07 Mallinckrodt Inc. Bifunctional metal chelating conjugates
KR20080099279A (ko) * 2006-02-24 2008-11-12 말린크로트, 인코포레이티드 이관능성 레조르시놀, 티오레조르시놀, 및 디티오레조르시놀 유도체 금속 킬레이팅 컨쥬게이트
US8193347B2 (en) * 2006-03-14 2012-06-05 Mallinckrodt Llc Metal complexes of tetraazamacrocycle derivatives
CA2645666A1 (en) * 2006-03-15 2007-09-20 Mallinckrodt Inc. Chelating conjugates having a substituted aromatic moiety and derivatives thereof
MX2008011905A (es) 2006-03-21 2008-09-30 Genentech Inc Terapia de combinacion.
CA2656918A1 (en) * 2006-06-22 2007-12-27 Vaccinex, Inc. Anti-c35 antibodies for treating cancer
AU2007272604B2 (en) 2006-07-10 2013-08-01 The Regents Of The University Of California Luminescent 1-hydroxy-2-pyridinone chelates of lanthanides
CN103044550A (zh) 2006-09-01 2013-04-17 津莫吉尼蒂克斯公司 Il-31单克隆抗体的可变区序列和使用方法
US20080241061A1 (en) * 2006-11-21 2008-10-02 Lanza Gregory M Methods of imaging employing chelating agents
GB0624587D0 (en) * 2006-12-08 2007-01-17 Univ Muenchen Tech Chelating agent
WO2008092120A1 (en) * 2007-01-25 2008-07-31 Lumiphore, Inc. Multi-color time resolved fluorophores based on macrocyclic lanthanide complexes
WO2008105473A1 (ja) * 2007-02-28 2008-09-04 National University Corporation Chiba University 抗悪性腫瘍薬
US20110038865A1 (en) 2007-06-26 2011-02-17 University Of Miami Antibody- endostatin fusion protein and its variants
ES2660036T3 (es) 2007-12-07 2018-03-20 Zymogenetics, Inc. Moléculas de anticuerpo humanizadas específicas para IL-31
WO2009082485A1 (en) 2007-12-26 2009-07-02 Vaccinex, Inc. Anti-c35 antibody combination therapies and methods
JP2009215238A (ja) * 2008-03-11 2009-09-24 Osaka Univ 希土類発光プローブ
ES2525065T3 (es) 2008-04-11 2014-12-17 Merrimack Pharmaceuticals, Inc. Ligadores de seroalbúmina humana y sus conjugados
WO2010000714A2 (en) * 2008-07-04 2010-01-07 Oslo Universitetssykehus Hf Radioimmunoconjugate kit
WO2010051544A2 (en) * 2008-10-31 2010-05-06 Lumiphore, Inc. Rapid homogeneous diagnostic testing platform based on lanthanide fluorescent resonance energy transfer
DK2411411T3 (da) 2009-03-25 2016-11-07 Hoffmann La Roche Nye anti-alpha5beta1-antistoffer og anvendelser deraf
EP2470513B1 (en) 2009-08-24 2014-10-08 Lumiphore, Inc. Macrocyclic hopo chelators
EP3263562A1 (en) * 2009-12-24 2018-01-03 Lumiphore, Inc. Radiopharmaceutical complexes
KR101253100B1 (ko) * 2010-02-16 2013-04-10 경북대학교 산학협력단 폴리아자마크로사이클릭 화합물, 그 제조 방법 및 생의학적 적용
EP2569335B1 (en) 2010-05-14 2018-08-22 Orega Biotech Methods of treating and/or preventing cell proliferation disorders with il-17 antagonists
US11453652B2 (en) 2013-03-15 2022-09-27 Lumiphore, Inc. Di-macrocycles
PL3148581T3 (pl) 2014-05-30 2020-05-18 Henlix Biotech Co., Ltd. Przeciwciała przeciwko receptorowi naskórkowego czynnika wzrostu (EGFR)
US10562946B2 (en) 2014-06-20 2020-02-18 Genentech, Inc. Chagasin-based scaffold compositions, methods, and uses
ES2830392T3 (es) 2014-07-23 2021-06-03 Ohio State Innovation Foundation Métodos y composiciones relacionados con fragmentos de anticuerpo que se unen a la glicoproteína 72 asociada a tumores (TAG-72)
GB201421162D0 (en) 2014-11-28 2015-01-14 Ge Healthcare As Lanthanide complex formulations
US20180208658A1 (en) 2015-04-03 2018-07-26 Eureka Therapeutics, Inc. Constructs targeting afp peptide/mhc complexes and uses thereof
JP6952605B2 (ja) 2015-04-24 2021-10-20 ジェネンテック， インコーポレイテッド 多特異性抗原結合タンパク質
JP7072576B2 (ja) 2016-09-16 2022-05-20 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗ｐｄ－１抗体
US11274157B2 (en) 2017-01-12 2022-03-15 Eureka Therapeutics, Inc. Constructs targeting histone H3 peptide/MHC complexes and uses thereof
EP3615574A4 (en) 2017-04-26 2021-02-24 Eureka Therapeutics, Inc. CONSTRUCTIONS SPECIFICALLY RECOGNIZING GLYPICANE 3 AND USES OF SUCH LATEST
FR3069245B1 (fr) * 2017-07-21 2019-07-26 Guerbet Ligands macrocycliques lipophiles, leurs complexes ainsi que leurs utilisations medicales
KR20200130831A (ko) 2018-03-14 2020-11-20 베이징 슈안이 파마사이언시스 컴퍼니, 리미티드 항-클라우딘 18.2 항체
EP3784294A4 (en) * 2018-04-27 2022-01-05 University of Iowa Research Foundation COMPOSITIONS FOR CHELATING METALS AT LOW TEMPERATURES
CN112469440A (zh) 2018-06-18 2021-03-09 优瑞科生物技术公司 靶向***特异性膜抗原(psma)的构建体和其用途
KR20220006613A (ko) * 2019-05-10 2022-01-17 얀센 바이오테크 인코포레이티드 마크로사이클릭 킬레이터 및 이의 사용 방법
CN112300279A (zh) 2019-07-26 2021-02-02 上海复宏汉霖生物技术股份有限公司 针对抗cd73抗体和变体的方法和组合物
CN110818795B (zh) 2020-01-10 2020-04-24 上海复宏汉霖生物技术股份有限公司 抗tigit抗体和使用方法
CA3200975A1 (en) * 2020-11-10 2022-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of use thereof
KR20240116755A (ko) 2021-12-17 2024-07-30 상하이 헨리우스 바이오테크, 인크. 항-ox40 항체, 다중 특이적 항체 및 이의 사용 방법
AU2022411573A1 (en) 2021-12-17 2024-06-27 Shanghai Henlius Biologics Co., Ltd. Anti-ox40 antibodies and methods of use

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) * 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4472509A (en) * 1982-06-07 1984-09-18 Gansow Otto A Metal chelate conjugated monoclonal antibodies
US4454106A (en) * 1982-06-07 1984-06-12 Gansow Otto A Use of metal chelate conjugated monoclonal antibodies
SE8301395L (sv) * 1983-03-15 1984-09-16 Wallac Oy Kelatiserande foreningar med funktionella grupper vilka tillater kovalent koppling till bio-organiska molekyler
US4678667A (en) * 1985-07-02 1987-07-07 501 Regents of the University of California Macrocyclic bifunctional chelating agents
US4885363A (en) * 1987-04-24 1989-12-05 E. R. Squibb & Sons, Inc. 1-substituted-1,4,7-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
EP0232751B1 (en) * 1986-01-23 1991-09-11 E.R. Squibb & Sons, Inc. 1-substituted-4,7,10-triscarboxymethyl-1,4,7,10-tetraazacyclododecane and analogs
GB8603537D0 (en) * 1986-02-13 1986-03-19 Parker D Conjugate compound
DE3625417C2 (de) * 1986-07-28 1998-10-08 Schering Ag Tetraazacyclododecan-Derivate
US5057302A (en) * 1987-02-13 1991-10-15 Abbott Laboratories Bifunctional chelating agents
DE3713842A1 (de) * 1987-04-22 1988-11-17 Schering Ag Substituierte cyclische komplexbildner, komplexe und komplexsalze, verfahren zu deren herstellung und diese enthaltende pharmazeutische mittel
US5006643A (en) * 1987-06-24 1991-04-09 The Dow Chemical Company Process for preparing isothiocyanato functionalized metal complexes
US4994560A (en) * 1987-06-24 1991-02-19 The Dow Chemical Company Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
GB8719041D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8719042D0 (en) * 1987-08-12 1987-09-16 Parker D Conjugate compounds
DE68925904T2 (de) * 1988-05-25 1996-10-31 The United States Of America, Represented By The Secretary, U.S. Department Of Commerce, Springfield, Va. Makrocyclische chelate und verwendungsverfahren
PT90959B (pt) * 1988-06-24 1995-05-04 Dow Chemical Co Processo para a preparacao de quelantes macrociclicos bifuncionais, de seus complexos e seus conjugados com anticorpos

Also Published As

Publication number Publication date
EP0420942A1 (en) 1991-04-10
HUT70200A (en) 1995-09-28
FI103792B (fi) 1999-09-30
DE353450T1 (de) 1990-09-06
ATE120457T1 (de) 1995-04-15
AU3979489A (en) 1990-01-12
DK49390A (da) 1990-02-23
IE67273B1 (en) 1996-03-20
NZ229700A (en) 1993-01-27
NO179008C (no) 1996-07-17
HU894432D0 (en) 1992-02-28
US5435990A (en) 1995-07-25
CA1341373C (en) 2002-07-02
NO900869D0 (no) 1990-02-23
NO900869L (no) 1990-04-11
JPH04504247A (ja) 1992-07-30
NO179008B (no) 1996-04-09
BR8907507A (pt) 1991-06-11
HK60696A (en) 1996-04-19
KR900701765A (ko) 1990-12-04
EP0353450B1 (en) 1995-03-29
WO1989012631A1 (en) 1989-12-28
JP2831073B2 (ja) 1998-12-02
IE892045L (en) 1989-12-24
FI117889B (fi) 2007-04-13
FI103792B1 (fi) 1999-09-30
DK175393B1 (da) 2004-09-20
FI982303A (fi) 1998-10-23
FI906368A0 (fi) 1990-12-21
HU219485B (hu) 2001-04-28
FI982303A0 (fi) 1998-10-23
DK49390D0 (da) 1990-02-23
ES2013978A4 (es) 1990-06-16
DE68921941T2 (de) 1995-07-27
DE68921941D1 (de) 1995-05-04
EP0353450A1 (en) 1990-02-07
AU634167B2 (en) 1993-02-18
GR900300034T1 (en) 1991-07-31
KR0137930B1 (en) 1998-05-15

Similar Documents

Publication Publication Date Title
GR900300034T1 (en) Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates
ZA894792B (en) Macrocyclic bifunctional chelants,complexes thereof and their antibody conjugates
FI944973A0 (fi) Karboksiamidimodifioituja polyamiinikelaatinmuodostajia ja radioaktiivisia komplekseja ja konjugaatteja
NZ225070A (en) Functionalised polyamine chelants
AU628095B2 (en) Chelants possessing ortho ligating functionality and complexes thereof
EP0341304A4 (en) Improved ricin molecules and ricin toxin conjugates
FI953708A0 (fi) Menetelmä terapeuttisesti aktiivisten makrosyklisten bifunktionaalisten kelaatinmuodostajien, niiden kompleksien sekä niiden vasta-ainekonjugaattien valmistamiseksi

Legal Events

Date Code Title Description
KB Patent renewed
KB Patent renewed
KB Patent renewed